Trial reportWorld journal of clinical cases2024
Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy.
Trial report in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Evaluation of stem/stromal cell transplantation safety and efficacy in children diagnosed with cerebral palsy: A systematic review and meta-analysis of randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- Pooled it
- Efficacy and safety of exosomes from Wharton's Jelly-derived mesenchymal stem cells in traumatic brain injury.World journal of critical care medicine · 2025Trial
- Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation.World journal of methodology · 2025Trial
- Advances in the clinical application of mesenchymal stem cells for neurological disorders.Stem cell research & therapy · 2026Review
- Advancing regenerative therapies with umbilical cord-derived mesenchymal stem cells: A review.Biomolecules & biomedicine · 2025Review
- Neural progenitor cell transplantation results in structural and functional recovery in a rat model of cerebral palsy.Iranian journal of basic medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral palsy (CP) describes a group of disorders affecting movement, balance, and posture. Disturbances in motor functions constitute the main body of CP symptoms. These symptoms surface in early childhood and patients are affected for the rest of their lives. Currently, treatment involves various pharmacotherapies for different types of CP, including antiepileptics for epilepsy and Botox A for focal spasticity. However, none of these methods can provide full symptom relief. This has prompted researchers to look for new treatment modalities, one of which is mesenchymal stem cell therapy (MSCT). Despite being a promising tool and offering a wide array of possibilities, mesenchymal stem cells (MSCs) still need to be investigated for their efficacy and safety.
aimTo analyze the efficacy and safety of MSCT in CP patients.
methodsOur sample consists of four CP patients who cannot stand or walk without external support. All of these cases received allogeneic MSCT six times as 1 × 10
resultsWe found significant improvements in MAS scores after the intervention on both sides. Two months: Right
conclusionIn light of our findings, we believe that UC-MSC therapy has a positive effect on spasticity, and it partially improves motor functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.